Saturday, June 13, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 235 of 1,261
  1. US 11466274

    Modified gapmer oligonucleotides and methods of use

    Aligos Therapeutics, Inc. · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  2. US 11464737

    Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  3. US 11464755

    Antiviral treatments

    BioCryst Pharmaceuticals, Inc. · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  4. US 11464801

    Compositions and methods for treating cancer with anti-CD33 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  5. CA 3215723

    PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE

    ADVANCED ACCELERATOR APPLICATIONS [FR] · Granted Oct 6, 2022 · Expires Oct 1, 2042

    granted
  6. CA 3213326

    METHODES ET COMPOSITIONS POUR AMELIORER LA PRODUCTION ET LA SECRETION D'INSULINE

    ABBOTT LAB [US] · Granted Oct 6, 2022 · Expires Oct 1, 2042

    granted
  7. US 11459320

    Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  8. US 11459340

    Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  9. US 11459373

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  10. US 11459374

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  11. US 11459325

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  12. US 11459372

    Gene-edited natural killer cells

    CRISPR THERAPEUTICS AG · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  13. US 11459335

    N/O-linked Degrons and Degronimers for protein degradation

    C4 THERAPEUTICS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  14. US 11459357

    Polymyxin compounds

    SPERO THERAPEUTICS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  15. US 11459323

    Monocyclic β-lactam compound for treating bacterial infection

    Medshine Discovery Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  16. US 11459300

    Deuterated compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  17. US 11459381

    Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof

    UNIVERSITY OF CONNECTICUT · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  18. US 11458173

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  19. US 11458154

    Treatment of CYR61- and VEGF-mediated conditions

    VANDA PHARMACEUTICALS INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  20. US 11458171

    Engineering stem cells for cancer therapy

    China Medical University · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  21. US 11458174

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  22. US 11458094

    Compositions and methods for treating pulmonary edema or lung inflammation

    Regents of the University of Minnesota · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  23. US 11458116

    Method of improving sleep

    VANDA PHARMACEUTICALS INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  24. US 11458107

    Abiotic anti-VEGF nanoparticle

    The Regents of the University of California · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.